Adjunct therapy for COVID-19 requiring oxygen or ventilatory support

This indication refers to severe or critical coronavirus disease 2019 (COVID-19), an acute infection caused by SARS-CoV-2 that primarily targets the lower respiratory tract

This indication refers to severe or critical coronavirus disease 2019 (COVID-19), an acute infection caused by SARS-CoV-2 that primarily targets the lower respiratory tract Pharmacologic agents utilized under this indication serve as add-on therapies—frequently combined with standard foundational care like systemic corticosteroids or antivirals—to mitigate excessive inflammatory tissue injury and reduce mortality

It represents advanced pulmonary involvement characterized by severe hypoxemic respiratory failure, diffuse alveolar damage, microvascular thrombosis, and systemic hyperinflammation

It represents advanced pulmonary involvement characterized by severe hypoxemic respiratory failure, diffuse alveolar damage, microvascular thrombosis, and systemic hyperinflammation

Patients in this clinical state experience significant oxygenation impairment that necessitates supportive measures spanning supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation Pharmacologic agents utilized under this indication serve as add-on therapies—frequently combined with standard foundational care like systemic corticosteroids or antivirals—to mitigate excessive inflammatory tissue injury and reduc...

Patients in this clinical state experience significant oxygenation impairment that necessitates supportive measures spanning supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation Pharmacologic agents utilized under this indication serve as add-on therapies—frequently combined with standard foundational care like systemic corticosteroids or antivirals—to mitigate excessive inflammatory tissue injury and reduc...